{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:02:46Z","timestamp":1780117366131,"version":"3.54.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03572-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:26:32Z","timestamp":1776227192000},"page":"2752-2771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence for Sevelamer vs Calcium-Containing Phosphate Binders in Long-Term Effectiveness and Safety Among Patients with Non-Dialysis CKD: The REVEAL Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Ping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieguanxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichen","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"9","key":"3572_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu17091587","volume":"17","author":"S Raju","year":"2025","unstructured":"Raju S, Saxena R. Hyperphosphatemia in kidney failure: pathophysiology, challenges, and critical role of phosphorus management. Nutrients. 2025;17(9):1587. https:\/\/doi.org\/10.3390\/nu17091587.","journal-title":"Nutrients"},{"issue":"4","key":"3572_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","volume":"24","author":"AM Shaman","year":"2016","unstructured":"Shaman AM, Kowalski SR. Hyperphosphatemia management in patients with chronic kidney disease. Saudi Pharm J. 2016;24(4):494\u2013505. https:\/\/doi.org\/10.1016\/j.jsps.2015.01.009.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"3572_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","volume":"28","author":"D Russo","year":"2015","unstructured":"Russo D, Bellasi A, Pota A, Russo L, Di Iorio B. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol. 2015;28(1):73\u201380. https:\/\/doi.org\/10.1007\/s40620-014-0071-2.","journal-title":"J Nephrol"},{"issue":"4","key":"3572_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5414\/cnp73268","volume":"73","author":"CP Kovesdy","year":"2010","unstructured":"Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol. 2010;73(4):268\u201375. https:\/\/doi.org\/10.5414\/cnp73268.","journal-title":"Clin Nephrol"},{"key":"3572_CR5","unstructured":"Quarles LD, Kendrick J. Management of hyperphosphatemia in adults with chronic kidney disease [UpToDate]. 2025. https:\/\/www.uptodate.com\/contents\/management-of-hyperphosphatemia-in-adults-with-chronic-kidney-disease. Accessed 14 Nov 2025."},{"issue":"5","key":"3572_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000474959","volume":"45","author":"SK Bhandari","year":"2017","unstructured":"Bhandari SK, Liu IA, Kujubu DA, et al. Use of phosphorus binders among non-dialysis chronic kidney disease patients and mortality outcomes. Am J Nephrol. 2017;45(5):431\u201341. https:\/\/doi.org\/10.1159\/000474959.","journal-title":"Am J Nephrol"},{"issue":"4","key":"3572_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjmed.2012.08.018","volume":"126","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Smith N, et al. Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med. 2013;126(4):311\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2012.08.018.","journal-title":"Am J Med"},{"issue":"4","key":"3572_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2215\/cjn.05161107","volume":"3","author":"M Ketteler","year":"2008","unstructured":"Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125\u201330. https:\/\/doi.org\/10.2215\/cjn.05161107.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3572_CR9","unstructured":"Sanofi. Evaluation of Renvela in patients with chronic kidney disease not on dialysis and hyperphosphatemia in China (RECOVER) [ClinicalTrials.gov record: NCT03001011]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03001011. Accessed 14 Nov 2025."},{"issue":"1","key":"3572_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"3 Suppl 1","key":"3572_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-107. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.006.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3572_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ndt\/gfab184","volume":"37","author":"M Bozic","year":"2022","unstructured":"Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant. 2022;37(4):663\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfab184.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3572_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32065-2","volume":"8","author":"R Santamar\u00eda","year":"2018","unstructured":"Santamar\u00eda R, D\u00edaz-Tocados JM, de Pend\u00f3n-Ruiz Mier MV, et al. Increased phosphaturia accelerates the decline in renal function: a search for mechanisms. Sci Rep. 2018;8(1):13701. https:\/\/doi.org\/10.1038\/s41598-018-32065-2.","journal-title":"Sci Rep"},{"issue":"2","key":"3572_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/asn.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520\u20138. https:\/\/doi.org\/10.1681\/asn.2004070602.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3572_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/ki.2013.185","volume":"84","author":"JB Cannata-And\u00eda","year":"2013","unstructured":"Cannata-And\u00eda JB, Fern\u00e1ndez-Mart\u00edn JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5):998\u20131008. https:\/\/doi.org\/10.1038\/ki.2013.185.","journal-title":"Kidney Int"},{"issue":"2","key":"3572_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1681\/asn.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova T, Guti\u00e9rrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388\u201396. https:\/\/doi.org\/10.1681\/asn.2008060609.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3572_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","volume":"60","author":"AA Lopes","year":"2012","unstructured":"Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60(1):90\u2013101. https:\/\/doi.org\/10.1053\/j.ajkd.2011.12.025.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3572_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","volume":"72","author":"D Russo","year":"2007","unstructured":"Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72(10):1255\u201361. https:\/\/doi.org\/10.1038\/sj.ki.5002518.","journal-title":"Kidney Int"},{"issue":"4","key":"3572_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11255-009-9688-9","volume":"42","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage\u00a03\u22124. Int Urol Nephrol. 2010;42(4):1055\u201362. https:\/\/doi.org\/10.1007\/s11255-009-9688-9.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"3572_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/cjn.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286\u201391. https:\/\/doi.org\/10.2215\/cjn.05420709.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3572_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2215\/cjn.03820411","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487\u201393. https:\/\/doi.org\/10.2215\/cjn.03820411.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3572_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.2215\/cjn.12891211","volume":"7","author":"H Vlassara","year":"2012","unstructured":"Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934\u201342. https:\/\/doi.org\/10.2215\/cjn.12891211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3572_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","volume":"59","author":"MI Yilmaz","year":"2012","unstructured":"Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor\u00a023 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012;59(2):177\u201385. https:\/\/doi.org\/10.1053\/j.ajkd.2011.11.007.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3572_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/asn.2012070719","volume":"24","author":"CD Chue","year":"2013","unstructured":"Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage\u00a03 CKD. J Am Soc Nephrol. 2013;24(5):842\u201352. https:\/\/doi.org\/10.1681\/asn.2012070719.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3572_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000353569","volume":"38","author":"ME Seifert","year":"2013","unstructured":"Seifert ME, de las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol. 2013;38(2):158\u201367. https:\/\/doi.org\/10.1159\/000353569.","journal-title":"Am J Nephrol"},{"issue":"1","key":"3572_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5414\/cn107764","volume":"80","author":"S Soriano","year":"2013","unstructured":"Soriano S, Ojeda R, Rodr\u00edguez M, et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol. 2013;80(1):17\u201322. https:\/\/doi.org\/10.5414\/cn107764.","journal-title":"Clin Nephrol"},{"issue":"3","key":"3572_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/cjn.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014;9(3):543\u201352. https:\/\/doi.org\/10.2215\/cjn.05170513.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3572_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","volume":"22","author":"E Riccio","year":"2018","unstructured":"Riccio E, Sabbatini M, Bruzzese D, et al. Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol. 2018;22(3):529\u201338. https:\/\/doi.org\/10.1007\/s10157-017-1504-8.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"3572_CR29","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1681\/asn.2020040411","volume":"31","author":"ND Toussaint","year":"2020","unstructured":"Toussaint ND, Pedagogos E, Lioufas NM, et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020;31(11):2653\u201366. https:\/\/doi.org\/10.1681\/asn.2020040411.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3572_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1681\/asn.2021040554","volume":"33","author":"NM Lioufas","year":"2022","unstructured":"Lioufas NM, Pascoe EM, Hawley CM, et al. Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol. 2022;33(1):59\u201376. https:\/\/doi.org\/10.1681\/asn.2021040554.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3572_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ekir.2018.03.011","volume":"3","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Lu JL, Wall BM, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. Kidney Int Rep. 2018;3(4):897\u2013904. https:\/\/doi.org\/10.1016\/j.ekir.2018.03.011.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3572_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/0886022X.2022.2106872","volume":"44","author":"S Chen","year":"2022","unstructured":"Chen S, Chen L, Jiang H. Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study. Ren Fail. 2022;44(1):1309\u201318. https:\/\/doi.org\/10.1080\/0886022X.2022.2106872.","journal-title":"Ren Fail"},{"key":"3572_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.ki.5001994","volume":"105","author":"IG Nikolov","year":"2006","unstructured":"Nikolov IG, Joki N, Maizel J, Lacour B, Drueke TB, Massy ZA. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl. 2006;105:S16-23. https:\/\/doi.org\/10.1038\/sj.ki.5001994.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"3572_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamainternmed.2019.0045","volume":"179","author":"J Spoendlin","year":"2019","unstructured":"Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ. Cardiovascular outcomes of calcium-free vs calcium-based phosphate binders in patients 65\u00a0years or older with end-stage renal disease requiring hemodialysis. JAMA Intern Med. 2019;179(6):741\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0045.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"3572_CR35","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1097\/01.asn.0000100127.54107.57","volume":"14","author":"DA Goodkin","year":"2003","unstructured":"Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270\u20137. https:\/\/doi.org\/10.1097\/01.asn.0000100127.54107.57.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3572_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ekir.2019.03.016","volume":"4","author":"HA Stirnadel-Farrant","year":"2019","unstructured":"Stirnadel-Farrant HA, Karaboyas A, Cizman B, et al. Cardiovascular event rates among hemodialysis patients across geographical regions-a snapshot from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int Rep. 2019;4(6):864\u201372. https:\/\/doi.org\/10.1016\/j.ekir.2019.03.016.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3572_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/ndt\/gft232","volume":"29","author":"N Chen","year":"2014","unstructured":"Chen N, Wu X, Ding X, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant. 2014;29(1):152\u201360. https:\/\/doi.org\/10.1093\/ndt\/gft232.","journal-title":"Nephrol Dial Transplant"},{"key":"3572_CR38","unstructured":"National Institute for Health and Care Excellence. Surveillance report 2017\u2014Chronic kidney disease (stage\u00a04 or 5): management of hyperphosphataemia (2013) NICE guideline CG157, Chronic kidney disease in adults: assessment and management (2014) NICE guideline CG182 and Chronic kidney disease: managing anaemia (2015) NICE guideline NG8. London: National Institute for Health and Care Excellence (NICE); 2017. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551826\/pdf\/Bookshelf_NBK551826.pdf."},{"key":"3572_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/tcrm.S64657","volume":"11","author":"L Meng","year":"2015","unstructured":"Meng L, Fu B. Practical use of sevelamer in chronic kidney disease patients on dialysis in People\u2019s Republic of China. Ther Clin Risk Manag. 2015;11:705\u201312. https:\/\/doi.org\/10.2147\/tcrm.S64657.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"3572_CR40","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","volume":"22","author":"N Voormolen","year":"2007","unstructured":"Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22(10):2909\u201316. https:\/\/doi.org\/10.1093\/ndt\/gfm286.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"3572_CR41","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2169\/internalmedicine.7870-21","volume":"61","author":"A Oda","year":"2022","unstructured":"Oda A, Tanaka K, Saito H, et al. Association between serum inorganic phosphorus levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study. Intern Med. 2022;61(11):1653\u201362. https:\/\/doi.org\/10.2169\/internalmedicine.7870-21.","journal-title":"Intern Med"},{"issue":"4","key":"3572_CR42","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2215\/cjn.07450714","volume":"10","author":"JL G\u00f3rriz","year":"2015","unstructured":"G\u00f3rriz JL, Molina P, Cerver\u00f3n MJ, et al. Vascular calcification in patients with nondialysis CKD over 3\u00a0years. Clin J Am Soc Nephrol. 2015;10(4):654\u201366. https:\/\/doi.org\/10.2215\/cjn.07450714.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3572_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfw312","volume":"32","author":"S Habbous","year":"2017","unstructured":"Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(1):111\u201325. https:\/\/doi.org\/10.1093\/ndt\/gfw312.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"3572_CR44","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41581-021-00423-5","volume":"17","author":"H Noels","year":"2021","unstructured":"Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17(8):528\u201342. https:\/\/doi.org\/10.1038\/s41581-021-00423-5.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"3572_CR45","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41440-023-01230-0","volume":"46","author":"KW Kim","year":"2023","unstructured":"Kim KW, Koh HB, Kim HW, et al. Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD. Hypertens Res. 2023;46(6):1395\u2013406. https:\/\/doi.org\/10.1038\/s41440-023-01230-0.","journal-title":"Hypertens Res"},{"issue":"2","key":"3572_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","volume":"62","author":"W Braunlin","year":"2002","unstructured":"Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002;62(2):611\u20139. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00459.x.","journal-title":"Kidney Int"},{"issue":"4","key":"3572_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/ndt\/gfac222","volume":"38","author":"Y Okute","year":"2023","unstructured":"Okute Y, Shoji T, Shimomura N, et al. Serum phosphate as an independent factor associated with cholesterol metabolism in patients undergoing hemodialysis: a cross-sectional analysis of the DREAM cohort. Nephrol Dial Transplant. 2023;38(4):1002\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfac222.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3572_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2215\/cjn.12620921","volume":"17","author":"ZA Massy","year":"2022","unstructured":"Massy ZA, Merkling T, Wagner S, et al. Association of serum phosphate with efficacy of statin therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2022;17(4):546\u201354. https:\/\/doi.org\/10.2215\/cjn.12620921.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"3572_CR49","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2215\/cjn.01650211","volume":"6","author":"JF Navarro-Gonz\u00e1lez","year":"2011","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, de Muros Fuentes M, Donate-Correa J, Caza\u00f1a-P\u00e9rez V, Garc\u00eda-P\u00e9rez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(9):2272\u20139. https:\/\/doi.org\/10.2215\/cjn.01650211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"3572_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13100688","volume":"13","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn K, Puapatanakul P, Phannajit J, et al. Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia: a randomized controlled trial. Toxins (Basel). 2021;13(10):688. https:\/\/doi.org\/10.3390\/toxins13100688.","journal-title":"Toxins (Basel)"},{"issue":"2","key":"3572_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2215\/cjn.06800615","volume":"11","author":"L Patel","year":"2016","unstructured":"Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232\u201344. https:\/\/doi.org\/10.2215\/cjn.06800615.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03572-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:41Z","timestamp":1780116701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03572-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3572"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03572-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated due to retrospective open access.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lichen Hao is an employee of Sanofi, and reports owning stock in Sanofi. Ping Li, Zhe Feng, Xuefeng Sun, Shuang Liang, Chaofan Li, Xinru Guo, Xieguanxuan Xu, Xiangmei Chen and Guangyan Cai declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the ethical principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, Good Pharmacoepidemiology Practice, and the applicable local legislation. The protocol for this study was reviewed by the First Medical Center of Chinese PLA General Hospital Institutional Review Board (IRB); however, as all data used in this study were de-identified, the IRB deemed this study exempt from requiring approval or further review. Furthermore, the requirement for patients\u2019 informed consent was waived by the IRB because all personal identifiers were removed to ensure patient confidentiality. Permission was obtained from the database provider (Optum) to access and use the de-identified administrative claims data for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}